Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends

Research output: Contribution to journal › Review › Research › peer-review

Standard

Targeting the mTOR pathway in hepatocellular carcinoma : Current state and future trends. / Matter, Matthias S; Decaens, Thomas; Andersen, Jesper Bøje; Thorgeirsson, Snorri S.

In: Journal of Hepatology, 03.12.2013.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Matter, MS, Decaens, T, Andersen, JB & Thorgeirsson, SS 2013, 'Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2013.11.031

APA

Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2013). Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2013.11.031

Vancouver

Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. Journal of Hepatology. 2013 Dec 3. https://doi.org/10.1016/j.jhep.2013.11.031

Author

Matter, Matthias S ; Decaens, Thomas ; Andersen, Jesper Bøje ; Thorgeirsson, Snorri S. / Targeting the mTOR pathway in hepatocellular carcinoma : Current state and future trends. In: Journal of Hepatology. 2013.

Bibtex

@article{22ddb6dd056a48aea8d6059b0d4855ce,
title = "Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends",
abstract = "Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in response to nutrients, cellular energy stage and growth factors. mTOR is frequently up-regulated in cancer including hepatocellular carcinoma (HCC) and is associated with bad prognosis, poorly differentiated tumors, and earlier recurrence. Blocking mTOR with rapamycin and first generation mTOR inhibitors, called rapalogs, has shown promising reduction of HCC tumor growth in preclinical models. Currently, rapamycin/rapalogs are used in several clinical trials for the treatment of advanced HCC, and as adjuvant therapy in HCC patients after liver transplantation and TACE. A second generation of mTOR pathway inhibitors has been developed recently and is being tested in various clinical trials of solid cancers, and has been used in preclinical HCC models. The results of series of clinical trials using mTOR inhibitors in HCC treatment will emerge in the near future.",
author = "Matter, {Matthias S} and Thomas Decaens and Andersen, {Jesper B{\o}je} and Thorgeirsson, {Snorri S}",
note = "Published by Elsevier B.V.",
year = "2013",
month = dec,
day = "3",
doi = "10.1016/j.jhep.2013.11.031",
language = "English",
journal = "Journal of Hepatology, Supplement",
issn = "0169-5185",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Targeting the mTOR pathway in hepatocellular carcinoma

T2 - Current state and future trends

AU - Matter, Matthias S

AU - Decaens, Thomas

AU - Andersen, Jesper Bøje

AU - Thorgeirsson, Snorri S

N1 - Published by Elsevier B.V.

PY - 2013/12/3

Y1 - 2013/12/3

N2 - Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in response to nutrients, cellular energy stage and growth factors. mTOR is frequently up-regulated in cancer including hepatocellular carcinoma (HCC) and is associated with bad prognosis, poorly differentiated tumors, and earlier recurrence. Blocking mTOR with rapamycin and first generation mTOR inhibitors, called rapalogs, has shown promising reduction of HCC tumor growth in preclinical models. Currently, rapamycin/rapalogs are used in several clinical trials for the treatment of advanced HCC, and as adjuvant therapy in HCC patients after liver transplantation and TACE. A second generation of mTOR pathway inhibitors has been developed recently and is being tested in various clinical trials of solid cancers, and has been used in preclinical HCC models. The results of series of clinical trials using mTOR inhibitors in HCC treatment will emerge in the near future.

AB - Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in response to nutrients, cellular energy stage and growth factors. mTOR is frequently up-regulated in cancer including hepatocellular carcinoma (HCC) and is associated with bad prognosis, poorly differentiated tumors, and earlier recurrence. Blocking mTOR with rapamycin and first generation mTOR inhibitors, called rapalogs, has shown promising reduction of HCC tumor growth in preclinical models. Currently, rapamycin/rapalogs are used in several clinical trials for the treatment of advanced HCC, and as adjuvant therapy in HCC patients after liver transplantation and TACE. A second generation of mTOR pathway inhibitors has been developed recently and is being tested in various clinical trials of solid cancers, and has been used in preclinical HCC models. The results of series of clinical trials using mTOR inhibitors in HCC treatment will emerge in the near future.

U2 - 10.1016/j.jhep.2013.11.031

DO - 10.1016/j.jhep.2013.11.031

M3 - Review

C2 - 24308993

JO - Journal of Hepatology, Supplement

JF - Journal of Hepatology, Supplement

SN - 0169-5185

ER -

ID: 97135389